Ipsen posts strong nine-month 2026 sales growth and raises full-year guidance again
FROM THE WIRE · FINANCIALPOST.COM
Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1 Further upgraded FY 2026 financia…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA raised full-year guidance from a mid-sized pharma group is relevant for the stock and the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Year-to-date 2026 total sales grow 24.6% at constant exchange rates, or 23.0% as reported.
- 02The core portfolio achieves sales growth of 24.2%.
- 03Ipsen further upgraded its financial guidance for full-year 2026.